CD8A and hepatocellular carcinoma: Thus, our data, combined with the mechanistic insights into metformin’s actions, could be valuable in supporting the potential benefit of metformin treatment in reversing the immunosuppressive and CD8+ T-cell-exhausted tumor microenvironment in HCC patients [133].